HC Wainwright Reiterates “Buy” Rating for Perspective Therapeutics (NYSE:CATX)

Perspective Therapeutics (NYSE:CATX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 308.16% from the stock’s current price.

A number of other research analysts have also issued reports on the stock. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Oppenheimer dropped their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Monday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Stock Down 5.8 %

Shares of NYSE:CATX opened at $2.45 on Wednesday. The company has a 50-day simple moving average of $3.10 and a 200-day simple moving average of $7.02. Perspective Therapeutics has a one year low of $2.32 and a one year high of $19.05.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its position in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares during the period. Janus Henderson Group PLC grew its position in Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after buying an additional 355,685 shares during the period. Deerfield Management Company L.P. Series C grew its position in Perspective Therapeutics by 4.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock worth $9,375,000 after buying an additional 120,991 shares during the period. Octagon Capital Advisors LP grew its position in Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after buying an additional 882,528 shares during the period. Finally, State Street Corp lifted its holdings in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.